NEWS | BEAM Alliance

NEWS

Destiny Pharma: Second positive Phase 1 trial data from XF-73

Second positive Phase 1 trial data from XF-73 skin irritation study

Brighton, United Kingdom – 28 January 2019 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, which address the global problem of antimicrobial resistance (AMR), today announces positive data and the non-irritant classification for its XF-73 nasal gel from the second Phase 1 safety clinical study examining the drug’s potential to cause irritation when administered topically.

Full PR available here